Injectafer is a ferric carboxymaltose injection for the treatment of iron deficiency anemia (IDA). Injectafer is known to cause the electrolyte disorder known as hypophosphatemia. Hypophosphatemia can cause serious complications including coma, seizures, rhabdomyolysis, bone softening, arrhythmias, cardiac arrest and respiratory failure.
Call the dangerous drug specialists at Nadrich & Cohen, LLP today at 1-800-718-4658 for a free consultation if you or a loved one suffered serious complications after taking Injectafer. You can also use the live chat feature on this page to reach a live chat specialist, or complete the contact form on this page.
We offer a 100% free, confidential consultation. We are contingency lawyers so we only charge you a portion of your recovery if we obtain a recovery for you.
Injectafer Hypophosphatemia Side Effect
Hypophosphatemia is a low level of phosphate in the blood. The FDA lists it as an adverse reaction on Injectafer’s label. However, there is little to no information on the label regarding the serious complications arising from the condition or the drug’s tendency to cause severe hypophosphatemia.
The symptoms of hypophosphatemia include weakness, muscle dysfunction and weakness, trouble breathing, fatigue, mental status changes, white blood cell dysfunction, severe nausea and loss of appetite. Severe complications can result from hypophosphatemia, including:
- Bone softening
- Cardiac arrest
- Respiratory failure
Hypophosphatemia is typically treated with intravenous preparations of potassium phosphate. Oral supplementation is used when intravenous treatment is not available.
Contact the law firm of Nadrich & Cohen today to discuss your potential Injectafer side effect claim by calling 1-800-718-4658.
Injectafer Side Effects
A 2018 study found that patients who received ferric carboxymaltose (Injectafer) for treatment of IDA faced an increased risk of developing hypophosphatemia when compared to patients receiving ferumoxytol for IDA treatment instead. 29.1% of Injectafer patients had hypophosphatemia through the end of the five-week study, whereas none of the ferumoxytol patients did.
A 2016 study found that patients taking ferric carboxymaltose face a substantially higher risk of developing hypophosphatemia when compared to patients taking iron isomaltoside 1000. The study found that hypophosphatemia was caused by ferric carboxymaltose-induced hormone dysregulation: hypophosphatemic patients showed significantly increased levels of the phosphaturic hormone intact FGF-23.
Patients who develop hypophosphatemia are starting to file Injectafer lawsuits. This is because Injectafer’s label fails to warn of all the serious complications which can result from hypophosphatemia.
Lawyers Handling Injectafer Claims Nationwide
The dangerous drug specialists at Nadrich & Cohen, LLP have been handling dangerous drug lawsuits for decades. Our lawyers have over 70 years of combined legal experience and have recovered over $350 Million on behalf of clients. We have the knowledge and experience to obtain for you the largest possible recovery for your Injectafer side effect claim.
Our lawyers work solely on a contingency fee basis. This means that you are only charged a fee for our services if we obtain a recovery for you. There is never any upfront cost to you and you will never owe us a single penny out of your own pocket.
How To Join The Injectafer Lawsuit
Call us today at 1-800-718-4658 for a free consultation if you or a loved developed hypophosphatemia after using Injectafer. You can also fill out the free consultation request form on this page or use the live chat feature.